Marijuana is one of the most commonly used drugs in the United States, and use during adolescence--when the brain is still developing--has been proposed as a cause of poorer neurocognitive outcome. Nonetheless, research on this topic is scarce and often shows conflicting results, with some studies showing detrimental effects of marijuana use on cognitive functioning and others showing no significant long-term effects. The purpose of the present study was to examine the associations of marijuana use with changes in intellectual performance in two longitudinal studies of adolescent twins (n = 789 and n = 2,277). We used a quasiexperimental approach to adjust for participants' family background characteristics and genetic propensities, helping us to assess the causal nature of any potential associations. Standardized measures of intelligence were administered at ages 9-12 y, before marijuana involvement, and again at ages 17-20 y. Marijuana use was self-reported at the time of each cognitive assessment as well as during the intervening period. Marijuana users had lower test scores relative to nonusers and showed a significant decline in crystallized intelligence between preadolescence and late adolescence. However, there was no evidence of a dose-response relationship between frequency of use and intelligence quotient (IQ) change. Furthermore, marijuana-using twins failed to show significantly greater IQ decline relative to their abstinent siblings. Evidence from these two samples suggests that observed declines in measured IQ may not be a direct result of marijuana exposure but rather attributable to familial factors that underlie both marijuana initiation and low intellectual attainment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747759 | PMC |
http://dx.doi.org/10.1073/pnas.1516648113 | DOI Listing |
Prim Care Companion CNS Disord
January 2025
Department of Psychiatry, Iqraa International Hospital and Research Centre, Calicut, Kerala, India.
Chem Biodivers
January 2025
CSIR-CIMAP: Central Institute of Medicinal and Aromatic Plants CSIR, Botany and Pharmacognosy, Kukrail Picnic Spot Road, 226015, Lucknow, INDIA.
Cannabis sativa L. is an important medicinal plant with high commercial value. In recent years, the research interest in cannabidiol (CBD) and terpene-rich cannabis has been rapidly expanding due to their high therapeutic potential.
View Article and Find Full Text PDFClin Pract
January 2025
Fondazione Paolo Procacci, 00193 Roma, Italy.
Chronic non-cancer pain, defined by the Center for Disease Control and Prevention (CDC) as lasting beyond three months, significantly affects individuals' quality of life and is often linked to various medical conditions or injuries. Its management is complex. Cannabis, containing the key compounds Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), has garnered interest for its potential in pain management, though it remains controversial due to its psychoactive effects and illegal status in many countries.
View Article and Find Full Text PDFSubst Use Misuse
January 2025
Advancing New Standards in Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Oakland, California, USA.
Objective: To explore recently/currently pregnant people's experiences and views about cannabis use during pregnancy and their associated support for policies that punish pregnant people who use cannabis.
Methods: A market research firm administered a survey (May-June 2022) to pregnant and recently pregnant people ages 18-49 regarding their attitudes about cannabis use policies and practices. We used multivariable regression to assess whether cannabis use and beliefs are associated with support for punishing people who use cannabis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!